Table 1.

NCCN guidelines on chronic myelogenous leukemia

Indication	Testing	Frequency
At diagnosis before therapy	RT-qPCR and BM cytogenetics
	If BM is not feasible, FISH on PB is acceptable
During therapy	RT-qPCR	Every 3 months
	BM cytogenetics	BM cytogenetics At 3, 12, and 18 months
After complete cytogenetic response	ABL kinase domain mutation analysis	When initial response is inadequate
	RT-qPCR	Every 3–6 months
	BM cytogenetics to detect clonal evolution	As clinically indicated
	FISH is not recommended
Increasing levels of BCR-ABL1 transcripts	Evaluate compliance	As clinically indicated
	Repeat RT-qPCR in those with MMR
	BM cytogenetics in those without MMR
	Consider ABL kinase domain mutation analysis

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) Chronic Myelogenous Leukemia version 3.2013 (section CML-A, page 15; http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf). RT-qPCR, quantitative real time-PCR; BM, bone marrow; PB, peripheral blood; MMR, mismatch repair.